Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis

Arthritis and Rheumatism

Volumn 65, Issue 2, 2013, Pages 513-518

  Simonini, Gabriele ^a   Xu, Zhaohui ^b   Caputo, Roberto ^a   De Libero, Cinzia ^a   Pagnini, Ilaria ^a   Pascual, Virginia ^b   Cimaz, Rolando ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ARTICLE; BLAU SYNDROME; CASE REPORT; CHILD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG PULSE THERAPY; DRUG TOLERABILITY; ECZEMA; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA MACULA EDEMA; TENOSYNOVITIS; TOPICAL TREATMENT; TRANSCRIPTION REGULATION; UVEITIS; VISUAL IMPAIRMENT;

ANTIBODIES, MONOCLONAL; CHILD, PRESCHOOL; CRANIAL NERVE DISEASES; HUMANS; INTERLEUKIN-1BETA; MALE; SYNOVITIS; TREATMENT OUTCOME; UVEITIS;

EID: 84873814538     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37776     Document Type: Article

References (17)

1. Rose CD, Martin TM, Wouters CH,. Blau syndrome revisited. Curr Opin Rheumatol 2011; 23: 411-8.
2. Rose CD, Wouters CH, Meiorin S, Doyle TM, Davey MP, Rosenbaum JT, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006; 54: 3337-44.
3. Janssen CE, Rose CD, De Hertogh G, Martin TM, Bader Meunier B, Cimaz R, et al. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2-related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol 2012; 129: 1076-84.
4. Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Hafner R, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001; 29: 19-20.
5. Fink CW, Cimaz R,. Early onset sarcoidosis: not a benign disease. J Rheumatol 1997; 24: 174-7.
6. Raiji VR, Miller MM, Jung LK,. Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 2011; 15: 205-7.
7. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
8. Falcini F, Battini ML, Ceruso M, Cimaz R,. A 4-year-old with a rash. Lancet 1999; 354: 40.
9. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 150-64.
10. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54.
11. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
12. Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007; 56: 3805-13.
13. Pan Q, Mathison J, Fearns C, Kravchenko VV, Da Silva Correia J, Hoffman HM, et al. MDP-induced interleukin-1β processing requires Nod2 and CIAS1/NALP3. J Leukoc Biol 2007; 82: 177-83.
14. Martin TM, Zhang Z, Kurz P, Rose CD, Chen H, Lu H, et al. The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009; 60: 611-8.
15. Masumoto J, Yamazaki T, Ohta K, Nakayama J, Agematsu K,. Interleukin-1β suppression in Blau syndrome: comment on the article by Martin et al [letter]. Arthritis Rheum 2009; 60: 2544-5.
16. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J,. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
17. Foley KP, Wang L, Cooper D, Magid-Slav M, Lipshutz D, Connor J, et al. Identification of Blau syndrome disease signatures. Pediatr Rheumatol 2011; 9 Suppl 1: O25.